Group 1 - The core viewpoint is that the Hong Kong stock market is currently undervalued globally, with a continuing upward trend expected, particularly in the areas of dividends, technology (internet), and innovative pharmaceuticals [1][2] - The Hong Kong stock market has shown clear signs of bottoming out since the beginning of 2024, with significant changes observed across fundamentals, technicals, liquidity, and policy dimensions [1] - Liquidity in the Hong Kong market is abundant, supported by both southbound capital and increased local liquidity, which is further enhanced by external US dollar liquidity, providing a catalyst for the market [1] Group 2 - Despite a recent rapid increase, there are no concerns regarding valuation bubbles in the Hong Kong stock market, which remains undervalued compared to global markets [2] - The company maintains a long-term positive outlook on dividend assets and internet technology, emphasizing the importance of core technology assets in the new technology cycle [2] - The Hong Kong market has become the second-largest biotech financing hub globally since the Hong Kong Stock Exchange allowed unprofitable and revenue-less biotech companies to list in 2018, indicating a strong focus on innovative pharmaceuticals [2]
万家基金杨坤：港股仍是全球估值洼地 看好红利、科技和创新药三个方向
Zhi Tong Cai Jing·2025-08-15 11:30